These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8233286)

  • 1. Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule.
    Melekos MD
    Oncology; 1993; 50(6):450-5. PubMed ID: 8233286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours.
    Melekos MD; Zarakovitis IE; Fokaefs ED; Dandinis K; Chionis H; Bouropoulos C; Dauaher H
    Oncology; 1996; 53(4):281-8. PubMed ID: 8692531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes.
    Melekos MD; Zarakovitis I; Dandinis K; Fokaefs E; Chionis H; Dauaher H; Barbalias G
    Int Urol Nephrol; 1996; 28(4):499-509. PubMed ID: 9119635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study.
    Melekos MD; Dauaher H; Fokaefs E; Barbalias G
    J Urol; 1992 Feb; 147(2):371-5. PubMed ID: 1732596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule.
    Melekos MD; Chionis H; Pantazakos A; Fokaefs E; Paranychianakis G; Dauaher H
    J Urol; 1993 Apr; 149(4):744-8. PubMed ID: 8455235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
    Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
    Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
    Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
    Raitanen MP; Lukkarinen O
    Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of recurrence of superficial tumors of the bladder with intravesical epirubicin].
    Lancina Martín JA; García Pérez M; Arrabal Martín M; Vilches Cocovi E
    Actas Urol Esp; 1990; 14(2):112-4. PubMed ID: 2378265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.
    Shuin T; Kubota Y; Noguchi S; Hosaka M; Miura T; Kondo I; Fukushima S; Ishizuka E; Furuhata A; Moriyama M
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S52-6. PubMed ID: 7994787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical epirubicin in the prophylaxis of superficial bladder cancer.
    Sengör F; Beysel M; Erdoğan K; Erol A; Tuzluoğlu D
    Int Urol Nephrol; 1996; 28(2):201-6. PubMed ID: 8836789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.
    Okamura K; Murase T; Obata K; Ohshima S; Ono Y; Sakata T; Hasegawa Y; Shimoji T; Miyake K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S31-5. PubMed ID: 7994783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group.
    Okamura K; Kinukawa T; Tsumura Y; Otani T; Itoh H; Kobayashi H; Matsuura O; Kobayashi M; Fukatsu T; Ohshima S
    Eur Urol; 1998; 33(3):285-8; discussion 289. PubMed ID: 9555553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
    Segawa N; Nishida T; Takahara K; Nomi H; Azuma H; Katsuoka Y
    Hinyokika Kiyo; 2008 Nov; 54(11):711-6. PubMed ID: 19068724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.